Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations-Reference-Cited by-同舟云学术

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

Published:2019-02-11 Issue:5 Volume:62 Page:2428-2446
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Bensinger Dennis¹,Stubba Daniel¹,Cremer Anjali²,Kohl Vanessa¹,Waßmer Theresa¹,Stuckert Johanna¹,Engemann Victoria¹,Stegmaier Kimberly²,Schmitz Katja¹,Schmidt Boris¹^ORCID

Affiliation:

1. Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, 64287 Darmstadt, Germany

2. Department of Pediatric Oncology, Dana−Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, United States

Funder

National Cancer Institute

Leukemia and Lymphoma Society

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01714

Reference42 articles.

1. ‘Acute myeloid leukemia: a comprehensive review and 2016 update’

2. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

3. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

4. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis

5. Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment;Current Medicinal Chemistry;2024-09

2. X-ray Structure-Guided Discovery of a Potent Benzimidazole Glutaminyl Cyclase Inhibitor That Shows Activity in a Parkinson’s Disease Mouse Model;Journal of Medicinal Chemistry;2024-05-31

3. Total Synthesis and Anti-Inflammatory Evaluation of Osajin, Scandenone and Analogues;Pharmaceuticals;2024-01-09

4. Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor;European Journal of Medicinal Chemistry;2023-08

5. Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia;BMC Chemistry;2023-07-12